Maxillofacial Plastic and Reconstructive Surgery

Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지

TARGETED MOLECULAR THERAPY IN A MURINE MODEL OF ORAL SQUAMOUS CELL CARCINOMA WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR

구강 편평상피세포암 마우스 모델에서 상피성장인자 수용체 억제제를 적용한 분자표적치료

  • Park, Young-Wook (Department of Oral and Maxillofacial Surgery, College of Dentistry, Kangnung National University)
  • 박영욱 (강릉대학교 치과대학 구강악안면외과학교실)
  • Published : 2009.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We determined the therapeutic effect of an epidermal growth factor receptor (EGFR)-specific monoclonal antibody (mAb), cetuximab (Erbitux) on the growth of oral squamous cell carcinoma (OSCC) xenografted in athymic nude mice. Experimental Design: We induced subcutaneous tumors by inoculating human tumor cell suspension into the right flank of nude mice. Nude mice with subcutaneous tumors were randomized to receive cetuximab alone, paclitaxel alone, cetuximab plus paclitaxel, or a placebo (control). Antitumor mechanisms of cetuximab were determined by immunohistochemical and apoptosis assays. Results: Cetuximab, paclitaxel, and cetuximab/paclitaxel combined therapy resulted in 50%, 52%, 67% in vivo inhibition of tumor proliferation, respectively. Tumors of mice treated with cetuximab plus paclitaxel demonstrated decreased PCNA-positive tumor cells and increased apoptotic tumor cells, which slowed growth of the murine tumors. Conclusion: These data show that EGFR can be a molecular target for the treatment of OSCC. And combination therapy with cetuximab and paclitaxel warrants further clinical study.

Keywords

References

  1. Kupferman ME, Myers JN : Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol Clin North Am 39(2) : 229, 2006 https://doi.org/10.1016/j.otc.2005.11.003
  2. Ries LA, Miller BA, Hartman AM et al : Cancer statistics review 1973-1988. National Cancer Institute, NIH Publications no 91-2789
  3. Pawson T : Protein modules and signalling networks. Nature 373(6515) : 573, 1995 https://doi.org/10.1038/373573a0
  4. Robinson DR, Wu YM, Lin SF : The protein tyrosine kinase family of the human genome. Oncogene 19(49) : 5548, 2000 https://doi.org/10.1038/sj.onc.1203957
  5. Ullrich A, Schlessinger J : Signal transduction by receptors with tyrosine kinase activity. Cell 61 : 203, 1990 https://doi.org/10.1016/0092-8674(90)90801-K
  6. Cohen S, Carpenter G, King L Jr : Epidermal growth factor receptor-kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255 : 1555, 1980
  7. Choi S, Myers JN : Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 87(2) : 191, 2008 https://doi.org/10.1177/154405910808700217
  8. Dassonville O, Formento JL, Francoual M et al : Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11 : 1873, 1993
  9. Zwick E, Bange Z, Ullrich A : Receptor tyrosine kinase signalling as a target for cancer intervention strategies. Endocr Relat Cancer 8(3) : 161, 2001 https://doi.org/10.1677/erc.0.0080161
  10. Park YW, Lee JW, Kim SH : Expressions of metastasisrelated factors in orthotopic tumor models of oral squamous cell carcinoma. J Kor Assoc Maxillofac Plast Reconstr Surgeons 30(6) : 529, 2008
  11. Mamot C, Drummond DC, Noble CO et al : Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65(24) : 11631, 2005 https://doi.org/10.1158/0008-5472.CAN-05-1093
  12. Yigitbasi OG, Younes MN, Doan D et al : Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64 : 7977, 2004 https://doi.org/10.1158/0008-5472.CAN-04-1477
  13. Younes MN, Yigitbasi OG, Park YW et al : Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation. Cancer Res 65 : 4716, 2005 https://doi.org/10.1158/0008-5472.CAN-04-4196
  14. Park YW, Younes MN, Jasser SA et al: AEE788, a dual tyrosine kinase inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 11 : 1963, 2005 https://doi.org/10.1158/1078-0432.CCR-04-1665
  15. Harari PM : Epidermal growth factor receptor inhibition strategies in oncology. Endoc Rel Cancer : 11 689, 2004 https://doi.org/10.1677/erc.1.00600
  16. Marshall J : Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107 : 1207, 2006 https://doi.org/10.1002/cncr.22133
  17. Sano D, Myers JN : Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26 : 645, 2007 https://doi.org/10.1007/s10555-007-9082-y
  18. Harding J, Burtness B : Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 41(2) : 107, 2005 https://doi.org/10.1358/dot.2005.41.2.882662
  19. Cunningham MP, Thomas H, Fan Z et al : Responses of human colorectal tumor cells to treatment with the antiepidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor Gefitinib. Cancer Res 66(15) : 7708, 2006 https://doi.org/10.1158/0008-5472.CAN-06-1000
  20. Karashima T, Sweeney P, Slaton JW et al : Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8 : 1253, 2002
  21. Eisenhauser EA, Vermorken JB : The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55 : 5, 1998 https://doi.org/10.2165/00003495-199855010-00002
  22. Schrijvers D, Vermorken JB : Role of taxoid in head and neck cancer. Oncologist 5 : 199, 2005 https://doi.org/10.1634/theoncologist.5-3-199
  23. Thaker PH, Yazici S, Nilsson MB et al : Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 11(13) : 4923, 2005 https://doi.org/10.1158/1078-0432.CCR-04-2060
  24. Yazici S, Kim SJ, Busby JE et al : Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 65(3) : 203, 2005 https://doi.org/10.1002/pros.20283
  25. Sumitomo M, Asano T, Asakuma J et al : ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10(2) : 794, 2004 https://doi.org/10.1158/1078-0432.CCR-0948-03
  26. Kttner C : Paclitaxel administration along with antiangiogenic therapy in head and neck squamous cell carcinoma xenograft model. Int Poster J Dent Oral Med 3(4) : poster93, 2001
  27. Kim S, Prichard CN, Younes MN et al : Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Cancer Ther 12(2) : 600, 2006 https://doi.org/10.1158/1078-0432.CCR-05-1325
  28. Kuwai T, Nakamura T, Sasaki et al : Phosphorylatd epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia 10(5) : 489, 2008